Literature DB >> 8528745

Clinical trials: specific problems associated with the use of a placebo-control group.

T J Cleophas1.   

Abstract

In order to test hypotheses prospectively with hard data and against placebo, the scientific method of clinical trials has been developed. The present paper focuses on specific problems associated with the use of a placebo control group. (a) The placebo highlights the ethical dilemma that a controlled clinical trial can place us in. (b) Also, in a trial an atmosphere is created of enhanced risks of placebo effects. (c) "Significantly different from placebo" does not necessarily mean clinically relevant. (d) A biased placebo period due to carry-over effect is a common problem of controlled trials with a cross-over or self-controlled design. (e) Likewise an asymmetric placebo group is also a common problem in parallel-group designs. (f) The response to a placebo is generally small in comparison with the response to active treatment and is therefore sometimes more susceptible to bias. It is emphasized that routinely accounting for such problems may further improve the powerful method of controlled clinical trials.

Keywords:  Biomedical and Behavioral Research

Mesh:

Substances:

Year:  1995        PMID: 8528745     DOI: 10.1007/bf00240142

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  20 in total

1.  Biotechnology--the enormous cost of success.

Authors:  R F Doolittle
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  The interpretation of epidemiologic studies.

Authors:  M Angell
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

3.  Should morbidity replace mortality as an endpoint for clinical trials in intensive care?

Authors:  A J Petros; J C Marshall; H K van Saene
Journal:  Lancet       Date:  1995-02-11       Impact factor: 79.321

4.  The importance of placebo effects.

Authors:  T J Cleophas
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272

5.  The continuing unethical use of placebo controls.

Authors:  K J Rothman; K B Michels
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

6.  The use of placebo controls.

Authors:  T J Cleophas
Journal:  N Engl J Med       Date:  1995-01-05       Impact factor: 91.245

7.  Statistical concepts fundamental to investigations.

Authors:  L E Moses
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

8.  Statistical concepts fundamental to investigations.

Authors:  T J Cleophas
Journal:  N Engl J Med       Date:  1985-10-17       Impact factor: 91.245

9.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Authors:  S Yusuf; C J Pepine; C Garces; H Pouleur; D Salem; J Kostis; C Benedict; M Rousseau; M Bourassa; B Pitt
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

10.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

View more
  3 in total

Review 1.  Crossover studies are a better format for comparing equivalent treatments than parallel-group studies.

Authors:  T J Cleophas; E M de Vogel
Journal:  Pharm World Sci       Date:  1998-06

2.  Can keeping clinical trial participants blind to their study treatment adversely affect subsequent care?

Authors:  Joseph C Blader
Journal:  Contemp Clin Trials       Date:  2005-03-03       Impact factor: 2.226

3.  Ethical Considerations for Acupuncture and Chinese Herbal Medicine Clinical Trials: A Cross-cultural Perspective.

Authors:  Christopher Zaslawski
Journal:  Evid Based Complement Alternat Med       Date:  2008-08-21       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.